The content is available as a PDF (456.1 KB).
. 2020 May 19;158(6):S-537. doi: 10.1016/S0016-5085(20)32037-0
Su1189 SAFETY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH PREEXISTING INFLAMMATORY BOWEL DISEASE AND MICROSCOPIC COLITIS
Shilpa Grover
, Alex Ruan
, Padma Srivoleti
, Anita Giobbie-Hurder
, Marta Braschi-Amirfarzan
, Amitabh Srivastava
, Elizabeth Buchbinder
, Patrick Ott
, F Stephen Hodi
, Kenneth Kehl
, Mark Awad
, Osama Rahma
Shilpa Grover
Find articles by Shilpa Grover
Alex Ruan
Find articles by Alex Ruan
Padma Srivoleti
Find articles by Padma Srivoleti
Anita Giobbie-Hurder
Find articles by Anita Giobbie-Hurder
Marta Braschi-Amirfarzan
Find articles by Marta Braschi-Amirfarzan
Amitabh Srivastava
Find articles by Amitabh Srivastava
Elizabeth Buchbinder
Find articles by Elizabeth Buchbinder
Patrick Ott
Find articles by Patrick Ott
F Stephen Hodi
Find articles by F Stephen Hodi
Kenneth Kehl
Find articles by Kenneth Kehl
Mark Awad
Find articles by Mark Awad
Osama Rahma
Find articles by Osama Rahma
Issue date 2020 May.
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
PMCID: PMC7237173